MDACC Study No:RTOG0834 ( NCT No: NCT00626990)
Title:Phase III trial on Concurrent and Adjuvant Temozolomide chemotherapy in non - 1p/19q deleted anaplastic glioma. The CATNON Intergroup trial.
Principal Investigator:John DeGroot
Treatment Agent:Temozolomide
Study Status:Closed
Study Description:The goal of the screening consent is to learn if you are eligible to take part
in the main research study. The goal of the clinical research study is to learn
if giving temozolomide in combination with radiation therapy can help to
control anaplastic glioma for a longer time than standard radiation therapy
alone. The safety of this combination treatment will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Brain; CNS
Phase of Study:Phase III
Treatment Agents:Temozolomide
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:NRG Oncology/CTSU and EOTRC
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:John DeGroot
Dept:Neuro Oncology
For Clinical Trial Enrollment:713-792-2883
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults